Initial clinical study results will inform pivotal clinical trial in U.S. and Europe...
Lark Health, the leading AI-powered digital care coaching company for the prevention and management of chronic conditions, and Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, today announced their expanded partnership where DOHC will offer Lark's Prevention program and CDC-recognized Diabetes Prevention program to their patients....
Selected by the National Center for Global Health and Medicine under the Ministry of Health, Labour and Welfare, Japan as "Projects for Global Growth of Medical Technologies, in 2023"...
Technology enables inference of subjective outcomes from routinely collected data...
ReddyPort announced that the US Food and Drug Administration (FDA) granted 510(k) premarket clearance for the ReddyPort elbow device used in non-invasive ventilation (NIV)....
Surgeons in the Division of Thoracic Surgery at JFK University Medical Center first in the State of New Jersey to perform this surgery...
According to the American Cancer Society, about 1 out of every 8 men will be diagnosed with prostate cancer during his lifetime...
Pacifica Salud Hospital has joined the Global Provider Network (GPN), ushering in a new era of streamlined and easy access for American consumers and self-funded employers to access one of Latin America's top healthcare providers....
Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted patients fulfill IVDR requirements in Europe. These tests are the first post-transplant monitoring NGS products to be approved under the new, more comprehensive regulation that came into force in May 2022 and confirm Devyser's two NGS products meet the established safety, efficacy, and quality requirements....
Optina Diagnostics' pioneering pivotal REPHRASE study, currently underway, is poised to revolutionize the diagnosis and management of Alzheimer's Disease (AD). This landmark study is focused on validating the novel awAIr™-Cerebral Amyloid Status (CAS) test, an innovative tool intended to provide physicians with definitive information about Alzheimer's pathology, enabling improved management of cognitive impairments....
